The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
September 5, 2022
View Complete Issue         Table of Contents 2019 
A Fixed-Dose Combination of Finasteride and Tadalafil (Entadfi) for BPH (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Fixed-Dose Combination of Finasteride and Tadalafil (Entadfi) for BPH (online only)
September 5, 2022 (Issue: 1658)
The FDA has approved Entadfi (Veru), a fixed-dose combination of the 5α-reductase inhibitor finasteride and the phosphodiesterase type 5 (PDE5) inhibitor tadalafil, for initial treatment of benign prostatic hyperplasia (BPH) in men with an...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Fixed-Dose Combination of Finasteride and Tadalafil (Entadfi) for BPH (online only)
Article code: 1658e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.